Author: Bicara Therapeutics Inc.

Posted Date:

May 13, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc.

May 13, 2026
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bicara Therapeutics Inc.

May 11, 2026
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

Bicara Therapeutics Inc.

May 4, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc.

April 3, 2026
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Bicara Therapeutics Inc.

March 30, 2026
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

Bicara Therapeutics Inc.

March 23, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc.

March 4, 2026
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Bicara Therapeutics Inc.

February 26, 2026
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Bicara Therapeutics Inc.

February 24, 2026
Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics Inc.

February 24, 2026